Biomarkers in heart failure.

Heart failure results not only from cardiac overload or injury but also from a complex interplay among genetic, neurohormonal, inflammatory, and biochemical changes acting on cardiac myocytes, the cardiac interstitium, or both. This review focuses on biomarkers for heart failure other than routinely determined laboratory values and discusses how these might be used in assessing and managing heart failure.

[1]  D. Muthu,et al.  Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2009 .

[2]  J. Sundström,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes , 2008 .

[3]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[4]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[5]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[6]  P. Ponikowski,et al.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.

[7]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[8]  D. Lloyd‐Jones,et al.  Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.

[9]  M. Pfeffer,et al.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. , 2007, Journal of the American College of Cardiology.

[10]  J. Januzzi,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study , 2007, Circulation.

[11]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[12]  M. Drazner,et al.  Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function , 2007, Hypertension.

[13]  C. Phillips,et al.  Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[14]  F. Crea,et al.  Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. , 2007, European heart journal.

[15]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[16]  J. Struck,et al.  Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. , 2007, Journal of the American College of Cardiology.

[17]  J. McMurray,et al.  Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. , 2007, European heart journal.

[18]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[19]  D. Morrow,et al.  Benchmarks for the Assessment of Novel Cardiovascular Biomarkers , 2007, Circulation.

[20]  S. Russell,et al.  Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels , 2007, Heart.

[21]  A. Maisel,et al.  Natriuretic peptides. , 2007, Journal of the American College of Cardiology.

[22]  Peipei Ping,et al.  Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. , 2006, Journal of the American College of Cardiology.

[23]  J. Hare,et al.  Nitroso–Redox Interactions in the Cardiovascular System , 2006, Circulation.

[24]  P. Ellinor,et al.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.

[25]  S. Hazen,et al.  Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.

[26]  J. Cohn,et al.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.

[27]  B. Pathik,et al.  Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. , 2006, American heart journal.

[28]  R. Schrier.  Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. , 2006, The American journal of medicine.

[29]  J. Cohn,et al.  The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). , 2006, Journal of cardiac failure.

[30]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[31]  Heart Failure Society Of America.  HFSA 2006 Comprehensive Heart Failure Practice Guideline. , 2006, Journal of cardiac failure.

[32]  J. Teerlink.  Endothelins: Pathophysiology and treatment implications in chronic heart failure , 2005, Current heart failure reports.

[33]  C. Price,et al.  B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[35]  J. Cohn,et al.  C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.

[36]  Y. Dohi,et al.  Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. , 2005, Journal of cardiac failure.

[37]  F. Recchia,et al.  Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. , 2005, Current vascular pharmacology.

[38]  Douglas L Mann,et al.  Targeted anticytokine therapy and the failing heart. , 2005, The American journal of cardiology.

[39]  P. Aukrust,et al.  Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. , 2005, The American journal of cardiology.

[40]  R. Vasan,et al.  Novel markers for heart failure diagnosis and prognosis , 2005, Current opinion in cardiology.

[41]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[42]  S. Devaraj,et al.  Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role , 2005, Current opinion in nephrology and hypertension.

[43]  K. Dickstein,et al.  Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[44]  P. Marino,et al.  Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. , 2004, Journal of cardiac failure.

[45]  G. Takemura,et al.  Critical Roles for the Fas/Fas Ligand System in Postinfarction Ventricular Remodeling and Heart Failure , 2004, Circulation research.

[46]  P. Mecocci,et al.  Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. , 2004, Journal of cardiac failure.

[47]  H. Shimomura,et al.  Urinary biopyrrins levels are elevated in relation to severity of heart failure. , 2004, Journal of the American College of Cardiology.

[48]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[49]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[50]  S. Anker,et al.  Uric acid and survival in chronic heart failure , 2004 .

[51]  J. Hare,et al.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.

[52]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[53]  V. Hasselblad,et al.  Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. , 2004, American heart journal.

[54]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[55]  K. Sliwa,et al.  Therapy of Ischemic Cardiomyopathy With the Immunomodulating Agent Pentoxifylline: Results of a Randomized Study , 2004, Circulation.

[56]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[57]  J. Cohn,et al.  The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. , 2004, European heart journal.

[58]  亀田 邦彦.  Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease : Possible role for left ventricular remodelling , 2004 .

[59]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[60]  M. Hayashi.  [Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction]. , 2004, Journal of cardiology.

[61]  F. van Lente,et al.  Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure , 2003, Circulation.

[62]  A. Shah,et al.  Oxidative stress in heart failure. More than just damage. , 2003, European heart journal.

[63]  H. Ishizaka,et al.  Matrix metalloproteinase; , 2022 .

[64]  T. Manolio.  Novel risk markers and clinical practice. , 2003, The New England journal of medicine.

[65]  G. Fonarow,et al.  Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.

[66]  P. Ponikowski,et al.  Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.

[67]  D. Levy,et al.  Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study , 2003, Circulation.

[68]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[69]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[70]  M. Zile,et al.  Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure: Effects on Left Ventricular Function and Structure , 2003, Circulation research.

[71]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[72]  김수경,et al.  제 2 형 당뇨병 환자 및 당뇨병과 심혈관질환이 없는 성인을 대상으로 조사한 심혈관계질환의 위험인자와 혈청 high sensitivity C - reactive protein 사이의 관련성 비교 , 2002 .

[73]  C Guijarro,et al.  High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. , 2001, Circulation.

[74]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[75]  W. Colucci,et al.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[76]  L. Zanolla,et al.  Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[77]  J. Emparanza,et al.  Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. , 2000, Circulation.

[78]  永谷 憲歳.  Hemodynamic,Renal,and Hormonal Effects of Adrenomedullin Infusion in Patients with Congestive Heart Failure , 2000 .

[79]  H. Knapp,et al.  Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. , 1999, Circulation.

[80]  G. Maurer,et al.  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. , 1998, Journal of the American College of Cardiology.

[81]  R. Nagai,et al.  Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.

[82]  S. Yamaguchi,et al.  Serum levels of soluble form of Fas molecule in patients with congestive heart failure. , 1997, The American journal of cardiology.

[83]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[84]  K. Kangawa,et al.  Plasma adrenomedullin concentration in patients with heart failure. , 1996, The Journal of clinical endocrinology and metabolism.

[85]  J. Burnett,et al.  Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.

[86]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[87]  P. Heinrich,et al.  Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6 , 1990, Hepatology.

[88]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[89]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[90]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[91]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[92]  E. Braunwald,et al.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.

[93]  E. Braunwald,et al.  Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. , 1962, The New England journal of medicine.

[94]  H. F. Wood,et al.  A study of C-reactive protein in the serum of patients with congestive heart failure. , 1956, American heart journal.